Makvandi, Mehran
Samanta, Minu
Martorano, Paul
Lee, Hwan
Gitto, Sarah B.
Patel, Khushbu
Groff, David http://orcid.org/0000-0001-6897-2656
Pogoriler, Jennifer http://orcid.org/0000-0001-9366-4401
Martinez, Daniel
Riad, Aladdin
Dabagian, Hannah
Zaleski, Michael http://orcid.org/0000-0002-8419-1718
Taghvaee, Tara
Xu, Kuiying
Lee, Ji Youn
Hou, Catherine http://orcid.org/0000-0001-8905-8492
Farrel, Alvin
Batra, Vandana
Carlin, Sean D.
Powell, Daniel J. Jr http://orcid.org/0000-0002-5966-8908
Mach, Robert H.
Pryma, Daniel A. http://orcid.org/0000-0001-8978-4419
Maris, John M. http://orcid.org/0000-0002-8088-7929
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R35CA220500, R01CA219006)
U.S. Department of Energy (DE-SC0021066)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 30 March 2022
Accepted: 1 November 2022
First Online: 17 November 2022
Competing interests
: JM Maris is a paid consultant for Jubilent Radiopharma and Illumina Radiopharmaceuticals. DA Pryma discloses research grants from Siemens AG, 511 Pharma, and Progenics Pharmaceuticals Inc; research consultant positions with 511 Pharma, Progenics Pharmaceuticals Inc., Ipsen, and Actinium Pharmaceuticals Inc; and Clinical Trial Funding from Nordic Nanovector ASA. RH Mach, DA Pryma, and M Makvandi are listed as inventors on the USA Patent Number PCT/US2018/034398 held by the University of Pennsylvania that describes radiotherapeutic agent [<sup>211</sup>At]PTT. RH Mach is co-founder and scientific advisor for Trevarx biomedical which has licensed exclusive rights for [<sup>211</sup>At]PTT. All other authors are free from any competing interests.